|
JP3122128B2
(ja)
|
1989-12-21 |
2001-01-09 |
ノボ ノルディスク アクティーゼルスカブ |
ペプチド製剤
|
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
ATE234625T1
(de)
*
|
1994-12-23 |
2003-04-15 |
Novo Nordisk As |
Glp-1 zusammensetzungen mit verlängerter wirkdauer
|
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
|
DE19530865A1
(de)
|
1995-08-22 |
1997-02-27 |
Michael Dr Med Nauck |
Wirkstoff sowie Mittel zur parenteralen Ernährung
|
|
IL128332A0
(en)
|
1996-08-30 |
2000-01-31 |
Novo Nordisk As |
GLP-1 derivatives
|
|
JP2002506792A
(ja)
|
1998-02-27 |
2002-03-05 |
ノボ ノルディスク アクティーゼルスカブ |
Ｎ末端修飾ｇｌｐ−１誘導体
|
|
JP2003522099A
(ja)
|
1998-02-27 |
2003-07-22 |
ノボ ノルディスク アクティーゼルスカブ |
遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
|
|
WO1999043706A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Derivatives of glp-1 analogs
|
|
EP1061946B1
(en)
|
1998-02-27 |
2004-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
|
|
JP2002524514A
(ja)
*
|
1998-09-17 |
2002-08-06 |
イーライ・リリー・アンド・カンパニー |
タンパク質製剤
|
|
AU3357800A
(en)
|
1999-02-05 |
2000-08-25 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
|
JP2002542183A
(ja)
|
1999-04-16 |
2002-12-10 |
ノボ ノルディスク アクティーゼルスカブ |
成形可能な乾燥した医薬製剤
|
|
WO2001092206A1
(en)
|
2000-06-02 |
2001-12-06 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
AU2002308706A1
(en)
|
2001-06-01 |
2002-12-16 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
|
PL209734B1
(pl)
|
2002-02-20 |
2011-10-31 |
Emisphere Tech Inc |
Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
|
|
CN1787830A
(zh)
*
|
2003-05-14 |
2006-06-14 |
爱密斯菲尔科技公司 |
用于传送肽yy和pyy激动剂的组合物
|
|
BRPI0411165A
(pt)
*
|
2003-05-14 |
2006-07-11 |
Emisphere Tech Inc |
composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
|
|
BR122019021416A2
(https=)
|
2003-09-19 |
2019-12-21 |
|
|
|
ATE461217T1
(de)
|
2003-12-18 |
2010-04-15 |
Novo Nordisk As |
Glp-1-verbindungen
|
|
EP1696962A2
(en)
|
2003-12-18 |
2006-09-06 |
Novo Nordisk A/S |
Novel glp-1 analogues linked to albumin-like agents
|
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
US20070135338A1
(en)
|
2004-03-31 |
2007-06-14 |
Karyn O'neil |
Human GLP-1 mimetibodies, compositions, methods and uses
|
|
CN1968919A
(zh)
*
|
2004-04-16 |
2007-05-23 |
爱密斯菲尔科技公司 |
用于递送活性剂的8－（2－羟基苯氧基）辛基二乙醇胺和其盐
|
|
JP2007536268A
(ja)
*
|
2004-05-06 |
2007-12-13 |
エミスフェアー・テクノロジーズ・インク |
固体剤形の湿性ヘパリン
|
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
CA2572770A1
(en)
|
2004-07-08 |
2006-01-19 |
Novo-Nordisk A/S |
Polypeptide protracting tags comprising a tetrazole moiety
|
|
MX2007000510A
(es)
*
|
2004-07-12 |
2007-03-29 |
Emisphere Tech Inc |
Composiciones para suministrar peptido yy y agonistas de pyy.
|
|
WO2006037810A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
DK1831252T3
(da)
|
2004-12-22 |
2009-10-05 |
Lilly Co Eli |
GLP-1 analog fusionsproteinformuleringer
|
|
US20070128193A1
(en)
|
2004-12-22 |
2007-06-07 |
O'neil Karyn T |
GLP-1 agonists, compositions, methods and uses
|
|
ES2540929T3
(es)
*
|
2005-02-01 |
2015-07-14 |
Emisphere Technologies, Inc. |
Sistema de administración de retención gástrica y liberación controlada
|
|
US8603972B2
(en)
|
2005-03-18 |
2013-12-10 |
Novo Nordisk A/S |
Extended GLP-1 compounds
|
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
US20080200383A1
(en)
|
2005-04-08 |
2008-08-21 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
|
|
EP1968645A4
(en)
|
2005-12-22 |
2009-11-04 |
Centocor Ortho Biotech Inc |
HUMAN GLP-1 MIMETIC BODIES AND COMPOSITIONS FOR THE TREATMENT OF ADIPOSITAS AND RELATED DISEASES, METHODS AND APPLICATIONS
|
|
WO2007121318A2
(en)
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
|
US8679540B2
(en)
|
2006-06-09 |
2014-03-25 |
Flamel Technologies |
Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
|
|
WO2008011446A2
(en)
|
2006-07-18 |
2008-01-24 |
Centocor, Inc. |
Human glp-1 mimetibodies, compositions, methods and uses
|
|
WO2008019143A2
(en)
|
2006-08-04 |
2008-02-14 |
Amylin Pharmaceuticals, Inc |
Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition
|
|
US8501693B2
(en)
|
2006-08-04 |
2013-08-06 |
Amylin Pharmaceuticals, Llc |
Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
|
|
WO2008023050A1
(en)
|
2006-08-25 |
2008-02-28 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
BRPI0716539A2
(pt)
|
2006-09-07 |
2016-11-01 |
Emisphere Tech Inc |
métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
|
|
US20100069410A1
(en)
|
2006-12-01 |
2010-03-18 |
Emisphere Technologies Inc. |
acyclovir formulations
|
|
AR064623A1
(es)
|
2006-12-21 |
2009-04-15 |
Centocor Inc |
Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
|
|
EP1980245A1
(en)
|
2007-04-11 |
2008-10-15 |
Cephalon France |
Bilayer lyophilized pharmaceutical compositions and methods of making and using same
|
|
US20100080829A1
(en)
|
2007-04-11 |
2010-04-01 |
Cephalon France |
Lyophilized pharmaceutical compositions and methods of making and using same
|
|
GB0707662D0
(en)
*
|
2007-04-20 |
2007-05-30 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2009030771A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
EP2190872B1
(en)
|
2007-09-05 |
2018-03-14 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
|
JP2011506442A
(ja)
|
2007-12-11 |
2011-03-03 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
インスリン分泌性ペプチド結合体の製剤
|
|
JP2009274983A
(ja)
|
2008-05-14 |
2009-11-26 |
Kowa Co |
ニコチン酸アミドを含有する経口医薬組成物
|
|
EP2303226B1
(en)
|
2008-06-25 |
2016-03-23 |
Endo Pharmaceuticals Solutions Inc. |
Sustained delivery of exenatide and other polypeptides
|
|
JP5740689B2
(ja)
|
2008-08-18 |
2015-06-24 |
エンテラ バイオ エルティーディー． |
タンパク質の経口投与用の方法および組成物
|
|
SI2341905T2
(sl)
|
2008-09-04 |
2024-02-29 |
Amylin Pharmaceuticals, Llc |
Formulacije s podaljšanim sproščanjem z uporabo brezvodnih nosilcev
|
|
US8425968B2
(en)
|
2009-06-19 |
2013-04-23 |
Pepsico., Inc. |
Beverage preservative system containing pimaricin-cyclodextrin complex
|
|
US20120065255A1
(en)
|
2009-10-19 |
2012-03-15 |
Nagesh Palepu |
Cabazitaxel formulations and methods of preparing thereof
|
|
PT3345593T
(pt)
|
2009-11-13 |
2023-11-27 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
|
|
MY180661A
(en)
|
2009-11-13 |
2020-12-04 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
|
|
JP6006118B2
(ja)
|
2009-12-16 |
2016-10-12 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アナログ及び誘導体
|
|
AU2010339907A1
(en)
|
2009-12-16 |
2012-07-05 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
|
WO2011106378A2
(en)
|
2010-02-24 |
2011-09-01 |
Emisphere Technologies, Inc. |
Oral b12 therapy
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
JP6039569B2
(ja)
|
2010-11-09 |
2016-12-07 |
ノヴォ ノルディスク アー／エス |
二重アシル化されたｇｌｐ−１誘導体
|
|
SI2651398T1
(en)
*
|
2010-12-16 |
2018-04-30 |
Novo Nordisk A/S |
SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
PL2696687T3
(pl)
|
2011-04-12 |
2017-06-30 |
Novo Nordisk A/S |
Pochodne podwójnie acylowanej GLP-1
|
|
WO2012177929A2
(en)
|
2011-06-24 |
2012-12-27 |
Amylin Pharmaceuticals, Inc. |
Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
|
|
JP6006309B2
(ja)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
|
HRP20181447T1
(hr)
*
|
2012-03-22 |
2018-11-02 |
Novo Nordisk A/S |
Pripravci glp-1 peptida i njihova priprava
|
|
ES2965469T3
(es)
*
|
2012-03-22 |
2024-04-15 |
Novo Nordisk As |
Composiciones que comprenden un agente de suministro y preparación de estas
|
|
JP6517690B2
(ja)
*
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー／エス |
ペプチド及び送達剤を含む錠剤製剤
|
|
JP6224586B2
(ja)
|
2012-07-10 |
2017-11-01 |
武田薬品工業株式会社 |
注射用製剤
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
AU2013366692B2
(en)
|
2012-12-21 |
2017-11-23 |
Sanofi |
Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
|
|
KR102272671B1
(ko)
*
|
2013-05-02 |
2021-07-06 |
노보 노르디스크 에이/에스 |
Glp-1 화합물의 경구 투여
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
TW201609798A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
Ｅｘｅｎｄｉｎ－４胜肽類似物
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
AR099569A1
(es)
*
|
2014-02-28 |
2016-08-03 |
Novo Nordisk As |
Derivados de insulina y los usos médicos de estos
|
|
ES2741507T3
(es)
|
2014-04-07 |
2020-02-11 |
Novo Nordisk As |
Compuestos de glp-1 acilados doblemente
|
|
ES2630106T3
(es)
|
2014-10-07 |
2017-08-18 |
Cyprumed Gmbh |
Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
|
|
US20180263915A1
(en)
|
2015-01-29 |
2018-09-20 |
Novo Nordisk A/S |
Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
|
|
CN107708667A
(zh)
|
2015-06-16 |
2018-02-16 |
太阳医药高级研发有限公司 |
长效利拉鲁肽组合物
|
|
JP2018529749A
(ja)
|
2015-10-07 |
2018-10-11 |
シプルメット・ゲーエムベーハー |
ペプチド薬物を経口送達するための医薬製剤
|
|
US10946074B2
(en)
|
2016-03-03 |
2021-03-16 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
|
WO2018065634A1
(en)
|
2016-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
|
|
WO2018076074A1
(en)
|
2016-10-31 |
2018-05-03 |
Suda Ltd |
Mucosal active agent delivery
|
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
|
JP6898518B2
(ja)
|
2018-02-02 |
2021-07-07 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
|
|
MX2020010505A
(es)
|
2018-04-05 |
2021-01-15 |
Sun Pharmaceutical Ind Ltd |
Analogos novedosos de glp-1.
|
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|